Newsletter Subject

Tattoos May Be a Risk Factor for Lymphoma

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Sat, Jun 1, 2024 11:15 AM

Email Preheader Text

Weekly Review Saturday, June 01, 2024 THE BREAK ROOM CME SPOTLIGHT THE BREAK ROOM ADVERTISEMENT CME

[MEDPAGE TODAY]( Weekly Review Saturday, June 01, 2024 [Tattoos May Be a Risk Factor for Lymphoma]( [The Sickening Reality of 'White' Beauty Standards]( [Fish Oil Benefits or Harms; Statins at Age 85+; Doc's Hunger Strike for Bed Space]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Moving the Needle: Adopting New Evidence Into the Lower-Risk Myelodysplastic Syndrome Treatment Paradigm]( [PA Killed in Crossfire; Doc Gets 4 Years for Insider Trading; Wrongful Death Suit]( [COVID Shots Could Use Another Update, Study Suggests]( THE BREAK ROOM [Play Today's Wordosis: Our Medical Word Game]( ADVERTISEMENT [The Unexpected Skin Risk of Summer Margaritas by the Pool]( CME SPOTLIGHT [Improving Real-World Care For Veteran Patients With Hepatocellular Carcinoma: Strategies for Patient-Centered, Teams-Based Approaches]( [Former Surgeon General's Exorbitant ED Bill: Impact of 'Cover Your Ass' Care]( [GLP-1 Agonists in Adolescents and Young Adults; Benefits of Cancer Drug Trials]( [Young-Onset Dementia Tied to Preeclampsia]( CME SPOTLIGHT [The Future of NSCLC Care: Leveraging Biomarker Testing in the Management of Early-Stage, Resectable Disease]( [First U.S. Bird Flu Case With Respiratory Symptoms Emerges]( [Urologists Flee Mission Health]( [One in Nine Kids Have ADHD; Placebo Response in Trials; Befriending Former Patients]( CME SPOTLIGHT [Novel and Emerging Evidence in Early-Stage Breast Cancer]( [How Many Ditch GLP-1 Drugs? More Weekly Insulin Data; Ozempic for Alcohol Use?]( [Increase in CRC Cases in Younger Age Groups Extends to Preteens]( [Duchenne Drug Fails Confirmatory Trial; COVID Brain Changes; First-Seizure Clinics]( CME SPOTLIGHT [Employing Collaborative Care Strategies for the Management of Pediatric Patients With Hodgkin Lymphoma]( [Guillain-Barre Syndrome Rates After RSV Shots in Sync With Trial Data, CDC Says]( [MGMA: Docs 'Defy Gravity' of Inflation, Staff Shortages by Working Harder]( [Summer Heat Waves Pose a Deadly Threat to Patients With Mental Illness]( CME SPOTLIGHT [Applying the Latest Clinical Evidence to Treatment Plans for Pediatric Patients With Hodgkin Lymphoma]( [The Truth About Employee Turnover]( [High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Options]( ['Still Haunted By His Pleas to Get Out of There': What We Heard This Week]( CME SPOTLIGHT [Latest Clinical Evidence in Adult Diffuse Low-Grade Glioma]( [Washington State Hospitalists Set to Unionize]( [Clues From Bird Flu's Ground Zero on Dairy Farms in the Texas Panhandle]( [Smoking Isn't the Only Source of Nicotine Addiction in Town]( CME SPOTLIGHT [The Evolving Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: Integrating Biomarkers and Novel Treatment Approaches]( [Why Are Docs Still on X? Oral Allergy Syndrome PSA; Looking for a Girl in Healthcare]( [Brain Health Compromised by Climate Change]( [What If Medicaid Enrollees Were Given Cash Instead of Insurance Benefits?]( [Tirzepatide Sheds Pounds in Chinese Adults With BMI as Low as 24]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_DHE_Weekly?xid=nl_mpt_DHE_2024-06-01&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.